Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Lymphoma, Non-Hodgkin 3Lung Neoplasms 3Astrocytoma 3Recurrence 2Prostatic Neoplasms 2Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Small Intestine Cancer 1Small Cell Lung Carcinoma 1Sarcoma 1Salivary Gland Neoplasms 1Rhabdoid Tumor 1Paranasal Sinus Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Oligodendroglioma 1Neurofibroma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neurilemmoma 1Neoplasms, Unknown Primary 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Mouth Neoplasms 1Mesothelioma, Malignant 1

Interventions

Mitotane 2pembrolizumab 1milademetan 1cixutumumab 1antineoplaston AS 2-1 1antineoplaston A10 1Suramin 1Nivolumab 1Hydrocortisone 1Dichlorodiphenyldichloroethane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Adrenocortical Carcinoma × antineoplaston A10 × Clear all
NCT00003453 2018-05-09

Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer

Burzynski Research Institute

Phase 2 Terminated
6 enrolled 6 charts
Endocrine

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡